



**InSymbiosis will attend BioPartnering Europe, London  
Oct 9 2008, Montreal:**

Canadian-based InSymbiosis Discovery Inc (InSymbiosis) is pleased to announce their participation at BioPartnering Europe.

The purpose of this meeting is to bring innovative and emerging companies in the life science industries together with key members of the pharmaceutical, venture capital, and finance industries for partnering and collaboration.

The meeting will be held on October 13 and 14, 2008 in London England.

InSymbiosis is currently accepting appointments for meetings at this event.

If your schedules at BioPartnering don't allow our groups to meet or you are not attending BioPartnering, we are also available to meet outside of the conference schedule, so please contact us if you want to schedule a meeting.

For further information please contact Dean Wenham, President and CEO ([dwenham@insymbiosis.com](mailto:dwenham@insymbiosis.com)) or Verkin Khajadourian, Director of Business Development ([vkhajadourian@insymbiosis.com](mailto:vkhajadourian@insymbiosis.com); Tel: +1 (514) 807-9315 ext 156)

[www.insymbiosis.com](http://www.insymbiosis.com)

**About InSymbiosis**

InSymbiosis is a drug discovery and development services company based in Montreal, Canada. Our company's services span from early target and drug discovery through to IND and Phase I for both small molecule and biologics drugs. InSymbiosis have developed a unique paradigm for drug development based around a lean virtual model which leverages high quality and cost effective Canadian research and development resources. Key to the success of the InSymbiosis model is the effective use of project and program management skills to allow for the effective planning and execution of drug development programs.

**SERVICES**

- Drug Discovery
  - Target validation and transgenesis
  - Discovery Biology (Assay Development and HTS)
  - Discovery and Medicinal Chemistry
  - Discovery ADME, Bioanalytical Chemistry
  - Pharmacokinetic and Early Toxicology Studies including Cardiac Toxicity.
- Specialized Oncology Models and other animal models
- Pharmaceutical and Biologics Development and Formulation:
- Formulation development
  - Analytical Services
  - Stability Programs

- Regulatory Affairs and Auditing
- Regulatory Toxicology and Safety Pharmacology (GLP IND enabling studies as well as chronic non-clinical studies supporting clinical studies)
- Phase I clinical studies